Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences    GILD

Mes dernières consult.
Most popular
Business Summary
Logo Gilead Sciences
Discovers, develops and commercializes therapeutic products and treatments for life threatening diseases

Gilead Sciences, Inc. is a biopharmaceutical company, which discovers, develops and commercializes therapeutics for unmet medical need.

It focuses on human immunodeficiency virus and liver diseases, such as chronic hepatitis C virus infection & chronic hepatitis B virus infection, hematology & oncology, and cardiovascular & inflammation as well as respiratory diseases.

The company's products include Descovy, Odefsey, Genvoya, Stribild, Complera, Atripla, Truvada, Viread, Emtriva, Tybost, Vitekta, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, Hepsera, Zydelig, Letairis, Ranexa, Lexiscan, Cayston, Tamiflu, AmBisome and Macugen.

Gilead Sciences was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Number of employees : 9 000 persons.
Sales per Businesses
USD (in Million)%USD (in Million)%
Innovative Medicines32,639101.9%30,390100.2% -6.89%
Sales per Regions
USD (in Million)%USD (in Million)%
United States21,23466.3%19,35463.8% -8.85%
Europe7,52823.5%6,36521% -15.45%
Other Countries3,87712.1%2,1447.1% -44.7%
John Milligan561990President, Chief Executive Officer & Director
John Martin651990Executive Chairman
Kevin B. Young592016Chief Operating Officer
Robin L. Washington MBA, CPA542008Chief Financial Officer & Executive Vice President
Norbert W. Bischofberger, PhD611990Chief Scientific Officer & Executive VP-Research
Gregg H. Alton511999Executive VP-Corporate & Medical Affairs
Andrew Cheng MD, PhD-1999Executive VP-Clinical Research & Development
William A. Lee, PhD621991Executive Vice President-Research
John G. McHutchison, PhD-2010Executive Vice President-Clinical Research
George Pratt Shultz, PhD941996Director-Emeritus
Vote QuantityFloatCompany-owned sharesTotal Float
Share A 1 1,307,000,000 1,296,877,083 99.2% 0 0.0% 99.2%
The Vanguard Group, Inc. 92,319,272 7.06%
BlackRock Fund Advisors 68,773,670 5.26%
SSgA Funds Management, Inc. 55,413,217 4.24%
Fidelity Management & Research Co. 23,143,458 1.77%
Capital Research & Management Co. (Global Investors) 21,868,631 1.67%
Parnassus Investments 18,695,139 1.43%
T. Rowe Price Associates, Inc. 18,564,001 1.42%
Northern Trust Investments, Inc. 17,037,743 1.30%
Geode Capital Management LLC 15,469,196 1.18%
Norges Bank Investment Management 13,923,308 1.07%
Galapagos (GLPG) 6,760,70113.3%655,981,962 USD
Markets and indexes
- Nasdaq Stock Market
- Nasdaq Global Select Market
- Nasdaq 100 / SP 100, SP 500, Stoxx Americas 100, Stoxx Global 200, Stoxx NorthAmerica 50, Stoxx USA 50
Stock Exchange Codes
- Bloomberg Code :  GILD:US
- Reuters Code :  GILD.O
- Datastream Code :  @GILD
Company contact information
Gilead Sciences
333 Lakeside Drive
CA 94404 San Mateo, California
États-Unis (les)

Phone : +1 650 574 3000
Fax : +1 650 578 9264
Internet : http://www.gilead.com
Sector Bio Therapeutic Drugs
Connections : Gilead Sciences
Biotechnology Innovation Organization
The Aids Institute, Inc.
Kite Pharma, Inc.
University of Southern California
Collidion, Inc. (California)
Children's Discovery Museum
The Royal Australasian College of Physicians
CGI Pharmaceuticals, Inc.
Boys & Girls Club of Oakland
UCSF Benioff Children's Hospital Oakland
Partners In Health
Ohio Wesleyan University
Global Virus Network
InCarda Therapeutics, Inc.
Oxford BioTherapeutics Ltd.
Gilead Foundation
Acuitus, Inc.
© 2017 People , Fundamentals and Ownership    © 2017 Cofisem